Key Event Components

  • Key Event Components (KECs) are used to describe Key Events (KEs) in a computable way, by defining an action, processes, and object term that maps to controlled vocabulary and ontology terms.
  • KECs on this page can be filtered by the action, process, and object terms, as well as by source ontologies.
  • Link to source ontology terms are provided in cases where the URL was available when the ontology terms were added to the AOP-Wiki database.
  • A complete list of all KECs is available in TSV format on the Downloads Page.
Showing 451 to 475 of 1152 KECs
Clear Table Filters
ID Action Process Object Associated Key Events (KEs)
1006 increased cell death (GO:0008219) bone cell (CL:0001035) 1825: Increase, Cell death
1005 increased osteoclast differentiation (GO:0030316) 2089: Altered Bone Cell Homeostasis
1004 decreased osteoblast differentiation (GO:0001649) 2089: Altered Bone Cell Homeostasis
1003 occurrence abnormal bone remodeling (MP:0002998) 2090: Increase, Bone Remodeling
1002 occurrence positive regulation of bone resorption (GO:0045780) 2090: Increase, Bone Remodeling
1001 decreased bone mineralization (GO:0030282) 2090: Increase, Bone Remodeling
1000 abnormal DNA repair (GO:0006281) deoxyribonucleic acid (CHEBI:16991) 155: Inadequate DNA repair
999 abnormal cell differentiation (GO:0030154) 2245: Altered Cell Differentiation Signaling
997 increased neuron death (GO:0070997) 2098: Increase, Abnormal Neural Remodeling
995 decreased neurogenesis (GO:0022008) 2098: Increase, Abnormal Neural Remodeling
876 occurrence membrane fusion (GO:0061025) transmembrane protease serine 2 (PR:000016456) 1738: SARS-CoV-2 cell entry
886 decreased protein import into nucleus, translocation (GO:0000060) zinc finger protein GLI2 (PR:000008027) 2028: Decrease, GLI1/2 translocation to nucleus
885 decreased protein import into nucleus, translocation (GO:0000060) zinc finger protein GLI1 (PR:000008026) 2028: Decrease, GLI1/2 translocation to nucleus
883 decreased regulation of receptor activity (GO:0010469) smoothened (PR:000015288) 2027: Antagonism, Smoothened receptor
880 occurrence cellular response to exogenous dsRNA (GO:0071360) RNA viral genome (GO:0019022) 1901: Interferon-I antiviral response, antagonized by SARS-CoV-2
879 decreased type I interferon signaling pathway (GO:0060337) interferon beta (PR:000024939) 1901: Interferon-I antiviral response, antagonized by SARS-CoV-2
878 decreased type I interferon signaling pathway (GO:0060337) interferon alpha (PR:000024938) 1901: Interferon-I antiviral response, antagonized by SARS-CoV-2
877 occurrence endocytosis involved in viral entry into host cell (GO:0075509) cathepsin L1 (human) (PR:P07711) 1738: SARS-CoV-2 cell entry
869 increased toll-like receptor signaling pathway (GO:0002224) Toll-like receptor (PR:000001096) 1495: Substance interaction with the lung resident cell membrane components
866 increased Neoplasm of the lung (HP:0100526) lung (UBERON:0002048) 1670: Lung cancer
867 increased increased lung tumor incidence (MP:0008014) lung (UBERON:0002048) 1670: Lung cancer
577 increased Viral load (MESH:D019562) 1109: Increased, Deformed Wing Virus levels
871 increased Malignant mesothelioma (HP:0100001) mesothelioma (MESH:D008654) 1090: Increased, mesotheliomas
872 occurrence receptor binding (GO:0005102) angiotensin-converting enzyme 2 (PR:000003622) 1739: Binding to ACE2
889 decreased gene expression (GO:0010467) zinc finger protein GLI1 (PR:000008026) 2040: Decrease, GLI1/2 target gene expression